351 related articles for article (PubMed ID: 17521177)
1. The application of 3D-QSAR studies for novel cannabinoid ligands substituted at the C1' position of the alkyl side chain on the structural requirements for binding to cannabinoid receptors CB1 and CB2.
Durdagi S; Kapou A; Kourouli T; Andreou T; Nikas SP; Nahmias VR; Papahatjis DP; Papadopoulos MG; Mavromoustakos T
J Med Chem; 2007 Jun; 50(12):2875-85. PubMed ID: 17521177
[TBL] [Abstract][Full Text] [Related]
2. 3D-QSAR studies of arylpyrazole antagonists of cannabinoid receptor subtypes CB1 and CB2. A combined NMR and CoMFA approach.
Chen JZ; Han XW; Liu Q; Makriyannis A; Wang J; Xie XQ
J Med Chem; 2006 Jan; 49(2):625-36. PubMed ID: 16420048
[TBL] [Abstract][Full Text] [Related]
3. Development of CoMFA and CoMSIA models of affinity and selectivity for indole ligands of cannabinoid CB1 and CB2 receptors.
De Freitas GB; da Silva LL; Romeiro NC; Fraga CA
Eur J Med Chem; 2009 Jun; 44(6):2482-96. PubMed ID: 19249138
[TBL] [Abstract][Full Text] [Related]
4. Combined 3D QSAR and molecular docking studies to reveal novel cannabinoid ligands with optimum binding activity.
Durdagi S; Papadopoulos MG; Papahatjis DP; Mavromoustakos T
Bioorg Med Chem Lett; 2007 Dec; 17(24):6754-63. PubMed ID: 17980589
[TBL] [Abstract][Full Text] [Related]
5. C1'-cycloalkyl side chain pharmacophore in tetrahydrocannabinols.
Papahatjis DP; Nahmias VR; Nikas SP; Andreou T; Alapafuja SO; Tsotinis A; Guo J; Fan P; Makriyannis A
J Med Chem; 2007 Aug; 50(17):4048-60. PubMed ID: 17672444
[TBL] [Abstract][Full Text] [Related]
6. Pharmacophoric requirements for the cannabinoid side chain. Probing the cannabinoid receptor subsite at C1'.
Papahatjis DP; Nikas SP; Kourouli T; Chari R; Xu W; Pertwee RG; Makriyannis A
J Med Chem; 2003 Jul; 46(15):3221-9. PubMed ID: 12852753
[TBL] [Abstract][Full Text] [Related]
7. Homology models of the cannabinoid CB1 and CB2 receptors. A docking analysis study.
Montero C; Campillo NE; Goya P; Páez JA
Eur J Med Chem; 2005 Jan; 40(1):75-83. PubMed ID: 15642412
[TBL] [Abstract][Full Text] [Related]
8. Pharmacophoric requirements for cannabinoid side chains: multiple bond and C1'-substituted delta 8-tetrahydrocannabinols.
Papahatjis DP; Kourouli T; Abadji V; Goutopoulos A; Makriyannis A
J Med Chem; 1998 Mar; 41(7):1195-200. PubMed ID: 9544219
[TBL] [Abstract][Full Text] [Related]
9. Unsaturated side chain beta-11-hydroxyhexahydrocannabinol analogs.
Busch-Petersen J; Hill WA; Fan P; Khanolkar A; Xie XQ; Tius MA; Makriyannis A
J Med Chem; 1996 Sep; 39(19):3790-6. PubMed ID: 8809166
[TBL] [Abstract][Full Text] [Related]
10. Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2.
Brogi S; Corelli F; Di Marzo V; Ligresti A; Mugnaini C; Pasquini S; Tafi A
Eur J Med Chem; 2011 Feb; 46(2):547-55. PubMed ID: 21183257
[TBL] [Abstract][Full Text] [Related]
11. Novel 4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new CB2 cannabinoid receptors agonists: synthesis, pharmacological properties and molecular modeling.
Stern E; Muccioli GG; Millet R; Goossens JF; Farce A; Chavatte P; Poupaert JH; Lambert DM; Depreux P; Hénichart JP
J Med Chem; 2006 Jan; 49(1):70-9. PubMed ID: 16392793
[TBL] [Abstract][Full Text] [Related]
12. 3D-QSAR studies on cannabinoid CB1 receptor agonists: G-protein activation as biological data.
Salo OM; Savinainen JR; Parkkari T; Nevalainen T; Lahtela-Kakkonen M; Gynther J; Laitinen JT; Järvinen T; Poso A
J Med Chem; 2006 Jan; 49(2):554-66. PubMed ID: 16420041
[TBL] [Abstract][Full Text] [Related]
13. Combined CoMFA and CoMSIA 3D-QSAR study of benzimidazole and benzothiophene derivatives with selective affinity for the CB2 cannabinoid receptor.
Romero-Parra J; Chung H; Tapia RA; Faúndez M; Morales-Verdejo C; Lorca M; Lagos CF; Di Marzo V; David Pessoa-Mahana C; Mella J
Eur J Pharm Sci; 2017 Apr; 101():1-10. PubMed ID: 28137469
[TBL] [Abstract][Full Text] [Related]
14. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
Bhongade BA; Gadad AK
J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
[TBL] [Abstract][Full Text] [Related]
15. 3D-QSAR studies of boron-containing dipeptides as proteasome inhibitors with CoMFA and CoMSIA methods.
Zhu YQ; Lei M; Lu AJ; Zhao X; Yin XJ; Gao QZ
Eur J Med Chem; 2009 Apr; 44(4):1486-99. PubMed ID: 18771818
[TBL] [Abstract][Full Text] [Related]
16. QSAR study of a large set of 3-pyridyl ethers as ligands of the alpha4beta2 nicotinic acetylcholine receptor.
Zhang H; Li H; Ma Q
J Mol Graph Model; 2007 Jul; 26(1):226-35. PubMed ID: 17208024
[TBL] [Abstract][Full Text] [Related]
17. Exploring the substituent effects on a novel series of C1'-dimethyl-aryl Delta8-tetrahydrocannabinol analogs.
Krishnamurthy M; Gurley S; Moore BM
Bioorg Med Chem; 2008 Jul; 16(13):6489-500. PubMed ID: 18524604
[TBL] [Abstract][Full Text] [Related]
18. Development of a novel class of monocyclic and bicyclic alkyl amides that exhibit CB1 and CB2 cannabinoid receptor affinity and receptor activation.
Berglund BA; Fleming PR; Rice KC; Shim JY; Welsh WJ; Howlett AC
Drug Des Discov; 2000; 16(4):281-94. PubMed ID: 10807034
[TBL] [Abstract][Full Text] [Related]
19. Tricyclic pyrazoles. 3. Synthesis, biological evaluation, and molecular modeling of analogues of the cannabinoid antagonist 8-chloro-1-(2',4'-dichlorophenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide.
Murineddu G; Ruiu S; Loriga G; Manca I; Lazzari P; Reali R; Pani L; Toma L; Pinna GA
J Med Chem; 2005 Nov; 48(23):7351-62. PubMed ID: 16279795
[TBL] [Abstract][Full Text] [Related]
20. 1-Alkyl-2-aryl-4-(1-naphthoyl)pyrroles: new high affinity ligands for the cannabinoid CB1 and CB2 receptors.
Huffman JW; Padgett LW; Isherwood ML; Wiley JL; Martin BR
Bioorg Med Chem Lett; 2006 Oct; 16(20):5432-5. PubMed ID: 16889960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
